UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-4717861 (State or other ju ...

Financial Performance - Fourth quarter 2025 net income was $43.2 million, or $1.03 per diluted share, compared to $14.4 million, or $0.35 per diluted share in the same period of 2024[1]. - Adjusted operating income for Q4 2025 was $48.9 million, or $1.17 per diluted share, up from $33.2 million, or $0.80 per diluted share in Q4 2024[2]. - Net income for the twelve months ended December 31, 2025, was $170,028,000, a 43.1% increase compared to $118,828,000 in 2024[20]. - Basic earnings per share rose to $4.21 in 2025 from $2.97 in 2024, reflecting a 41.8% increase[21]. - Total revenues for the twelve months ended December 31, 2025, reached $1,416,541,000, a 23.2% increase from $1,150,200,000 in 2024[20]. - Adjusted operating income for Q4 2025 was $61,758,000, compared to $48,855,000 in Q4 2024, marking a 26.4% increase[24]. - Annualized ROE improved to 17.5% in Q4 2025 from 7.2% in Q4 2024[21]. Premiums and Underwriting - Gross written premiums for Q4 2025 reached $439.5 million, a 13.2% increase from $388.4 million in Q4 2024[3]. - Net written premiums for the year ended 2025 were $1.4 billion, a 25.2% increase from $1.1 billion in 2024[4]. - Net earned premiums for Q4 2025 were $356,800,000, up 21.6% from $293,240,000 in Q4 2024[20]. - Total gross written premiums for the twelve months ended December 31, 2025, reached $2,166,317,000, a 24.3% increase from $1,743,249,000 in 2024[29]. - Accident & Health gross written premiums increased by 50.9% in Q4 2025, totaling $67,297,000 compared to $44,594,000 in Q4 2024[29]. - The Agriculture and Credit (Re)insurance segment saw a dramatic increase of 193.2% in gross written premiums for the twelve months ended December 31, 2025, totaling $346,212,000 compared to $118,070,000 in 2024[29]. - Specialty Programs gross written premiums increased by 75.1% in Q4 2025, reaching $91,304,000 compared to $52,151,000 in Q4 2024[29]. - The Surety segment reported a 21.1% increase in gross written premiums for Q4 2025, totaling $45,876,000 compared to $37,889,000 in Q4 2024[29]. - Underwriting income for Q4 2025 was $41,008,000, significantly higher than $12,239,000 in Q4 2024[25]. Assets and Equity - Total assets increased to $4,791,852,000 in 2025 from $3,729,478,000 in 2024, representing a growth of 28.5%[19]. - Stockholders' equity rose to $1,009.6 million at December 31, 2025, a 5.0% increase from $961.4 million at September 30, 2025[9]. - Tangible stockholders' equity as of December 31, 2025, was $921,525,000, up from $706,651,000 in 2024[28]. - Book value per share increased by 26% to $24.92 as of December 31, 2025, from $19.77 at the end of 2024[3]. - Book value per share increased to $24.92 in 2025 from $19.79 in 2024, a growth of 25.0%[21]. Liabilities and Reserves - Total liabilities increased to $3,782,287,000 in 2025 from $2,935,479,000 in 2024, an increase of 28.9%[19]. - Reserves for losses and loss adjustment expenses increased to $2,318,894,000 in 2025 from $1,782,383,000 in 2024, a rise of 30.0%[19]. Investment Income - Net investment income for Q4 2025 was $23.5 million, an increase of $2.8 million compared to Q4 2024[7]. - Net investment income for the twelve months ended December 31, 2025, was $83,619,000, compared to $80,600,000 in 2024[25]. - Interest expense for the twelve months ended December 31, 2025, decreased to $7,919,000 from $9,496,000 in 2024[25]. Strategic Goals - The company aims to continue building and maintaining winning positions across the specialty insurance market, leveraging its diversified portfolio[2].

Exhibit 99.1 FOR IMMEDIATE RELEASE: CONTACT: Geoff High, Vice President of Investor Relations 303-604-3924 DMC GLOBAL REPORTS FOURTH QUARTER FINANCIAL RESULTS BROOMFIELD, Colo. - February 23, 2026 - DMC Global Inc. (Nasdaq: BOOM) today reported financial results for its fourth quarter ended December 31, 2025. During the fourth quarter, DMC made significant progress strengthening its balance sheet, management's primary objective for 2025. Net debt* was reduced by $11.4 million sequentially to $18.7 million, ...

On February 11, 2026, Great Lakes announced that it had entered into a definitive agreement for Saltchuk Resources, Inc. ("Saltchuk") to acquire the Company. The closing of the transaction will be subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino Act waiting period and the tender of shares representing at least one share more than a majority of Great Lakes' outstanding shares of common stock, and is expected to close in Q2 2026. Offshore Energy EXHIBIT 99.1 Great Lak ...

Financial Performance - ORIC Pharmaceuticals reported a net loss of $30.5 million for Q4 2025, compared to a net loss of $36.3 million in Q4 2024, reflecting a decrease of 16% year-over-year[15]. - Research and development (R&D) expenses for Q4 2025 were $25.9 million, down from $32.0 million in Q4 2024, a decrease of 19.5%[7]. - General and administrative (G&A) expenses increased to $8.7 million in Q4 2025 from $7.6 million in Q4 2024, a rise of 14.5%[7]. - Cash, cash equivalents, and investments totaled $392.3 million as of December 31, 2025, with an expected runway into the second half of 2028[7]. - Total assets increased to $408.9 million as of December 31, 2025, compared to $274.1 million in 2024, reflecting a growth of 49%[13]. Clinical Development - Rinzimetostat demonstrated a 55% PSA50 response rate and a 20% PSA90 response rate in mCRPC patients, with 76% achieving over 50% ctDNA reduction[5]. - Enozertinib showed a 67% overall response rate (ORR) in EGFR exon 20 NSCLC patients and a 100% intracranial ORR in patients with measurable CNS disease[5]. - ORIC anticipates initiating its first global Phase 3 registrational trial for rinzimetostat in mCRPC in the first half of 2026[6]. - The company expects multiple clinical data readouts for rinzimetostat and enozertinib in 2026, ahead of potential registrational trials[1]. Funding and Financial Position - The company raised $264 million from healthcare specialist funds, enhancing its financial position for future clinical trials[1].

Exhibit 99.1 News Release Allison Transmission Announces Fourth Quarter and Full Year 2025 Results INDIANAPOLIS, February 23, 2026 – Allison Transmission Holdings Inc. (NYSE: ALSN) today reported full year 2025 net sales of $3 billion with Adjusted EBITDA margin of 37.5 percent and net cash provided by operating activities of $836 million. David S. Graziosi, Chair, President and Chief Executive Officer of Allison commented, "Although 2025 presented meaningful macroeconomic challenges, we remained discipline ...

or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36866 Summit Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 37-1979717 (State or Other Jurisdiction of Incorporation or Organization) _____________________________ FORM 10-K _____________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ...

Exhibit 99.1 MEDIAALPHA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Fourth Quarter Revenue of $291 million and Record Transaction Value of $613 million; Record Transaction Value of $552 million in Property & Casualty Insurance Vertical Record Full-Year 2025 Revenue of $1.1 billion and Transaction Value of $2.2 billion Record Full-Year 2025 Net Income of $26.8 million and Adjusted EBITDA of $113.7 million (1) Board of Directors Doubles Share Repurchase Authorization to $100 million Los Ange ...

ACV Announces Fourth Quarter and Full-Year 2025 Results 15% Revenue Growth and Adjusted EBITDA Exceeding High-End of Guidance Full-Year 2025 Highlights First Quarter and Full-Year 2026 Guidance BUFFALO, February 23, 2026 — ACV (NYSE: ACVA), a leading digital automotive marketplace and data services partner for dealers and commercial clients, today reported results for its fourth quarter and full-year ended December 31, 2025. "We are very pleased with our fourth quarter results, with revenue at the high-end ...

Financial Performance - Keysight Technologies reported record revenue of $1.60 billion for Q1 2026, a 23% increase from $1.30 billion in Q1 2025[5] - Non-GAAP net income for Q1 2026 was $376 million, or $2.17 per share, compared to $317 million, or $1.82 per share in Q1 2025[5] - The company reported a GAAP net income of $281 million, or $1.63 per share, compared to $169 million, or $0.97 per share in Q1 2025[5] - GAAP net income for Q1 2026 was $281 million, with diluted EPS of $1.63, compared to $169 million and $0.97 in Q1 2025, representing a 66% increase in net income[21] - Non-GAAP net income for Q1 2026 was $376 million, with diluted EPS of $2.17, up from $317 million and $1.82 in Q1 2025, reflecting a 18.6% increase in net income[21] - Total revenue for Q1 2026 was $1,600 million, a 23% increase from $1,298 million in Q1 2025[30] Revenue Breakdown - The Communications Solutions Group (CSG) generated $1,124 million in revenue, reflecting a 27% year-over-year growth, with commercial communications up 33% and aerospace, defense, and government up 18%[3] - Revenue for the Communications Solutions Group increased by 27% to $1,124 million in Q1 2026, compared to $883 million in Q1 2025[24] - Revenue for the Electronic Industrial Solutions Group rose by 15% to $476 million in Q1 2026, up from $415 million in Q1 2025[25] - Revenue from Aerospace, Defense and Government increased by 18% to $366 million in Q1 2026, compared to $311 million in Q1 2025[30] - Revenue from Commercial Communications surged by 33% to $758 million in Q1 2026, up from $572 million in Q1 2025[30] Cash Flow and Assets - Cash flow from operations was $441 million, up from $378 million in the same quarter last year[5] - Free cash flow for Q1 2026 was $407 million, compared to $346 million in Q1 2025, indicating a 17.6% increase[27] - As of January 31, 2026, Keysight's cash, cash equivalents, and restricted cash totaled $2.20 billion[5] - Total assets increased to $11.481 billion as of January 31, 2026, compared to $11.301 billion at the end of October 2025[17] Future Projections - Keysight expects Q2 2026 revenue to be between $1.690 billion and $1.710 billion, representing approximately 30% year-over-year growth[4] - Non-GAAP earnings per share for Q2 2026 are projected to be between $2.27 and $2.33, based on approximately 173 million diluted shares[4] Gross Margin - The gross margin for the Communications Solutions Group remained stable at 68% for both Q1 2026 and Q1 2025[24] - The gross margin for the Electronic Industrial Solutions Group improved slightly to 62% in Q1 2026 from 61% in Q1 2025[25] Group Performance - The Electronic Industrial Solutions Group (EISG) achieved $476 million in revenue, a 15% increase from the previous year, driven by double-digit growth across automotive, energy, general electronics, and semiconductor markets[3]